Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Efficacy of abrocitinib monotherapy by body location in patients with moderate-to-severe atopic dermatitis: pooled results from phase 2b/3 studies
book_2
Source:
EADV Virtual - Poster session
calendar_today
Published on Medfyle:
November 2020
headphones
4
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Abrocitinib is a once-daily oral JAK inhibitor under investigation for AD.
- In this pooled analysis, patients treated with abrocitinib had greater improvements in extent and severity of AD in all body locations compared to placebo.
- Abrocitinib delivered change from baseline in erythema, induration, papulation, excoriation and lichenification.
- Dose-dependent reductions were consistent across all AD signs measured by EASI.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Jonathan I. Silverberg
George Washington University School of Medicine and Health Sciences, Washington, DC, USA